New Triple-Drug cocktail aims to tackle tough breast cancer
NCT ID NCT05422794
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new drug called ZEN003694 combined with immunotherapy (pembrolizumab) and chemotherapy (nab-paclitaxel) in 57 people with advanced triple-negative breast cancer. The goal is to find a safe dose and see if the combo can shrink tumors or slow the cancer's growth. It's a first step to see if this approach is worth studying further.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ZEN003694 (a BET inhibitor) combined with pembrolizumab (immunotherapy) and nab-paclitaxel (chemotherapy)
What this could lead to
If it works, this could lead to a more effective treatment for advanced triple-negative breast cancer, potentially shrinking tumors or slowing their growth.
What could go wrong
This is an early phase 1 trial with only 57 people, so it's mainly checking safety and dosing. The combination may cause side effects or not work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE III BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Boston Medical Center
RECRUITINGBoston, Massachusetts, 02118, United States
Contact
Contact Phone: •••-•••-••••
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
Contact Phone: •••-•••-••••
-
Laura and Isaac Perlmutter Cancer Center at NYU Langone
RECRUITINGNew York, New York, 10016, United States
Contact
Contact Email: •••••@•••••
-
NYU Langone Hospital - Long Island
RECRUITINGMineola, New York, 11501, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Vanderbilt Breast Center at One Hundred Oaks
RECRUITINGNashville, Tennessee, 37204, United States
Contact Phone: •••-•••-••••
Contact